Better Business / Member news
Burges Salmon advises on $5m medtech investment deal
Bristol-headquartered Burges Salmon has advised Cambridge medtech firm PlaqueTec on a $5m oversubscribed investment fundraiser to support the development of its cardiovascular disease data platform, BioCarta™.
The funding round, backed entirely by existing shareholders, will help advance PlaqueTec’s intracoronary liquid biopsy technology, which analyses biomarkers at the site of coronary plaque formation to support more targeted treatment programmes for cardiovascular disease.
The Burges Salmon team was led by senior associate Katie Carter, partner Alex Lloyd and solicitor Sophie Dicks.
Katie Carter said: “PlaqueTec is building a genuinely differentiated data asset at the intersection of cardiovascular research, clinical insight and therapeutic development.
“This successful fundraise is a strong endorsement of both the company’s technology and its long-term strategy. We’re pleased to have supported PlaqueTec on this important milestone and look forward to seeing the BioCarta platform continue to gain momentum.”
Mark Ebner added: “We’re grateful to Alex, Katie, Sophie and the Burges Salmon team for their outstanding support, sector insight and clear, commercial advice throughout the transaction.”
Bristol-headquartered Burges Salmon has advised Cambridge medtech firm PlaqueTec on a $5m oversubscribed investment fundraiser
All photos: Burges Salmon
Burges Salmon are member of the Bristol24/7 Better Business network, an initiative to help businesses thrive while creating a positive impact on Bristol and the people who live here. As part of their membership, businesses can publish member news stories like this. For more information, visit my.bristol247.com/better-business
Read next:
Our newsletters emailed directly to you
